T. Conroy

发表

Use of differential item functioning analysis to assess the equivalence of translations of a questionnaire

P. Fayers, M. Hjermstad, N. Aaronson, 2003, Quality of Life Research.

Predictive factors of positive circumferential resection margin after radiochemotherapy for rectal cancer: the French randomised trial ACCORD12/0405 PRODIGE 2.

T. Conroy, A. Leroux, I. Soubeyran, 2013, European journal of cancer.

Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - general approach and initial results for physical functioning.

Bernhard Holzner, Galina Velikova, Wei-Chu Chie, 2010, European journal of cancer.

Activity of vinorelbine in gastrointestinal cancers.

T. Conroy, 2002, Critical reviews in oncology/hematology.

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

T. Conroy, P. Laurent-Puig, M. Ychou, 2014, British Journal of Cancer.

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

T. Conroy, M. Ychou, A. Kramar, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Pierre Michel, Olivier Bouché, Jaafar Bennouna, 2011, The New England journal of medicine.

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychometric evaluation of an item bank for computerized adaptive testing of the EORTC QLQ-C30 cognitive functioning dimension in cancer patients

M. Taphoorn, M. Groenvold, M. Petersen, 2017, Quality of Life Research.

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC

B. Chauffert, J. Pignon, T. Conroy, 2013, European journal of cancer.

Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17

T. Conroy, C. Touraine, C. Mollevi, 2020, BMC Medical Research Methodology.

T. Conroy, J. Blazeby, 2003, Expert review of anticancer therapy.

Quality of life in patients with advanced colorectal cancer: what has been learnt?

T. Conroy, B. Glimelius, B. Glimelius, 2003, European journal of cancer.

Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg

R. Labianca, D. Kerr, W. Scheithauer, 1998 .

Factors of the evolution of fatigue dimensions in patients with breast cancer during the 2 years after surgery

F. Guillemin, T. Conroy, C. Rotonda, 2020, International journal of cancer.

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Bernard Leduc, Franck Bonnetain, Olivier Bouché, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

L. Quéro, T. Conroy, C. Borg, 2019, Clinical colorectal cancer.

Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.

T. Conroy, S. Gourgou-Bourgade, M. Jarlier, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2012, European journal of cancer.

Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

T. Conroy, Y. Bécouarn, O. Bouché, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate end points for overall survival and local control in neoadjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial.

T. Conroy, M. Ducreux, O. Bouché, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.

T. Conroy, M. Ychou, E. Assenat, 2018, Journal of Clinical Oncology.

Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.

T. Conroy, M. Ychou, M. Ducreux, 2010 .

Preoperative chemoradiotherapy in esophageal cancer

T. Conroy, 2004 .

[Bisphosphonates, pain and quality of life in metastatic breast cancer patients: a literature review].

T. Conroy, C. Roemer-Bécuwe, I. Krakowski, 2003, Bulletin du cancer.

Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer.

M. Koller, T. Conroy, D. Alderson, 2001, European journal of cancer.

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

T. Conroy, Y. Bécouarn, O. Bouché, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): Randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study).

B. Chauffert, T. Conroy, M. Ychou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer

T. Conroy, C. Fournier, O. Bouché, 2008, Oncology.

Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.

T. Conroy, E. Van Cutsem, B. Nordlinger, 2005, The Lancet. Oncology.

Fluorouracil should continue to be incorporated in the treatment of localized esophageal cancer.

T. Conroy, A. Adenis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.

T. Conroy, M. Ychou, M. Ducreux, 2005, European journal of cancer.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

T. Conroy, E. Van Cutsem, J. Tabernero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2011, International journal of cancer.

Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

T. Conroy, M. Ychou, M. Ducreux, 2009, British Journal of Cancer.

Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)

T. Conroy, M. Ychou, M. Ducreux, 2007 .

T. Conroy, M. Deblock, L. Uwer, 2007, Current opinion in oncology.

Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Christophe Hennequin, Bernard Denis, Pierre-Luc Etienne, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up

T. Conroy, P. Romestaing, S. Gourgou-Bourgade, 2011 .

Cost-Minimisation Analysis in First-Line Treatment of Metastatic Colorectal Cancer in France: XELOX versus FOLFOX-6

T. Conroy, M. Ychou, M. Ducreux, 2011, Oncology.

Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer.

M. Koller, T. Conroy, O. Sezer, 2003, European journal of cancer.

Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.

B. Chauffert, T. Conroy, M. Ducreux, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.

T. Conroy, P. Rougier, D. Wagener, 1996, European journal of cancer.

Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

T. Conroy, M. Ychou, M. Ducreux, 2008, British Journal of Cancer.

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

T. Conroy, E. Van Cutsem, J. Tabernero, 2005, Clinical colorectal cancer.

Quality of life in advanced colorectal cancer.

F. Guillemin, T. Conroy, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?

K. Van Steen, A. Bottomley, T. Conroy, 2006, European journal of cancer.

Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial

T. Conroy, M. Jarlier, A. Lambert, 2017, PloS one.

[Multisite validation study of questionnaire assessing out-patient satisfaction with care questionnaire in ambulatory chemotherapy or radiotherapy treatment].

S. Schraub, T. Conroy, B. Asselain, 2006, Bulletin du cancer.

Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments

F. Guillemin, T. Conroy, S. Causeret, 2022, Quality of Life Research.

Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer

T. Conroy, M. Ducreux, L. Schwarz, 2021, Cancers.

Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic colorectal cancer.

C. Tournigand, T. Conroy, O. Bouché, 2006, Gastroenterologie clinique et biologique.

Validation of the French version of the colorectal-specific quality-of-life questionnaires EORTC QLQ-CR38 and FACT-C

F. Guillemin, T. Conroy, C. Rotonda, 2008, Quality of Life Research.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial

T. Conroy, M. Déjardin, J. Bosset, 2004 .

Phase II study of sequential high-dose methotrexate (MTX) and 5-fluorouracil (F) alternated with epirubicin (E) and cisplatin (P) [FEMTX-P] in advanced gastric cancer.

T. Conroy, D. Wagener, A. de Graeff, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[Natural history and development of bone metastasis. Apropos of 429 cases].

T. Conroy, É. Luporsi, L. Malissard, 1988, Bulletin du cancer.

International Psychometric Validation of an EORTC Quality of Life Module Measuring Cancer Related Fatigue (EORTC QLQ-FA12)

A. Bottomley, T. Conroy, W. Chie, 2017, Journal of the National Cancer Institute.

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45.

N. Aaronson, M. Sprangers, A. Bottomley, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[Acute leukemia secondary to the treatment of multiple sclerosis with chlorambucil].

T. Conroy, P. Lederlin, F. Streiff, 1985, Revue neurologique.

[Standards, options and recommendations for tumor markers in colorectal cancer].

T. Conroy, J. Bidart, B. Buecher, 2002, Bulletin du cancer.

Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI).

T. Conroy, G. Deplanque, C. Borg, 2016 .

Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.

T. Conroy, M. Barberi-Heyob, J. Merlin, 1995, Anti-Cancer Drugs.

Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments

F. Guillemin, T. Conroy, S. Causeret, 2022, Quality of Life Research.

Item response models for the longitudinal analysis of health-related quality of life in cancer clinical trials

C. Lavergne, T. Conroy, S. Gourgou, 2016, BMC Medical Research Methodology.

VINORELBINE IN EPIDERMOID ESOPHAGEAL

T. Conroy, M. Glabbeke, J. Seitz, 2018 .

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.

T. Conroy, C. Borg, V. Boige, 2020, Journal of Clinical Oncology.

Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.

J. Pignon, T. Conroy, M. Ducreux, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Chemotherapy for pancreatic cancer: the rise of multidrug regimens.

T. Conroy, I. Borbath, D. Malka, 2018, The lancet. Gastroenterology & hepatology.

Preoperative (preop) radiotherapy (RT) + 5FU/folinic acid (FA) in T3,4 rectal cancers: Preliminary results of the FFCD 9203 randomized trial.

T. Conroy, J. Bosset, O. Bouché, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study.

T. Conroy, M. Ychou, M. Ducreux, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The SCOPE of definitive chemoradiotherapy in locally advanced esophageal cancer: what direction for the future?

T. Conroy, G. Créhange, 2016, Journal of thoracic disease.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, E. Deutsch, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

T. Conroy, J. Tabernero, A. Figer, 2001 .

EC3 COST-MINIMIZATION ANALYSIS OF CAPECITABINE + OXALIPLATIN (XELOX) VS. INFUSIONAL 5-FU/LV + OXALIPLATIN (FOLFOX-6) AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) IN THE FRENCH SETTING

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Brain metastases from epithelial ovarian carcinoma.

T. Conroy, D. Spaëth, B. Weber, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.

R. Abrams, J. Berlin, T. Conroy, 2022, JAMA oncology.

Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III preliminary results of preoperative fluorouracil (F) and cisplatin (P) versus surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC 94012-FFCD 9703 trial.

J. Pignon, T. Conroy, M. Ychou, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial

T. Conroy, M. Ychou, M. Ducreux, 2007 .

[Cisplatin, 5-FU and preoperative radiotherapy in esophageal epidermoid cancer. Multicenter phase II FFCD 8804 study].

T. Conroy, J. Faivre, J. Seitz, 1998, Gastroenterologie clinique et biologique.

Consolidation chemotherapy after definite concurrent chemoradiation in patients with non-operable esophageal cancer: Is it useful?

T. Conroy, A. Adenis, F. Castan, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: a French cooperative study.

J. Pignon, T. Conroy, M. Ducreux, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Development of a Clinical–Biological Model to Assess Tumor Progression in Metastatic Pancreatic Cancer: Post Hoc Analysis of the PRODIGE4/ACCORD11 Trial

T. Conroy, J. Salleron, A. Ayav, 2022, Cancers.

Assessing quality of life in patients with colorectal cancer: an update of the EORTC quality of life questionnaire.

M. Sprangers, M. Koller, T. Conroy, 2007, European journal of cancer.

Surgical resection with and without chemotherapy in oesophageal cancer

T. Conroy, J. Bosset, J. Triboulet, 2002, The Lancet.

Influence of age on chemoradiotherapy outcome in patients with rectal cancer: Exploratory analysis from the phase III study ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive.

T. Conroy, D. Arsène, O. Bouché, 2008, Gastroenterologie clinique et biologique.

Phase III, randomized, open-label study of capecitabine (X) plus oxaliplatin (XELOX) vs. infusional 5-FU/LV plus oxaliplatin (FOLFOX-6) first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): Findings from an interim safety analysis

T. Conroy, M. Ychou, M. Ducreux, 2005 .

Carcinoma of the colon

T. Conroy, P. Rougier, P. Lasser, 2001, British Journal of Cancer.

A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.

T. Conroy, G. Auclerc, D. Khayat, 1996, European journal of cancer.

[Delayed urticaria with oxaliplatin].

T. Conroy, A. Barbaud, P. Tréchot, 2000, Gastroenterologie clinique et biologique.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

J. Pignon, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preoperative Chemoradiotherapy (CT-RT) Improves Local Control in T3-4 Rectal Cancers: Results of the FFCD 9203 Randomized Trial

T. Conroy, O. Bouché, P. Romestaing, 2005 .

COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)

T. Conroy, F. Penault-Llorca, M. Campone, 2022, Clinical Medicine Insights. Oncology.

A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer.

T. Conroy, P. Arveux, C. Mariette, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

S. Culine, T. Conroy, M. Ychou, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

T. Conroy, J. Lacy, P. Allen, 2016, The Lancet. Oncology.

Metastatic renal cell carcinoma

T. Conroy, F. Guillemin, É. Luporsi, 2015, Radiopaedia.org.

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

M. Buyse, T. Conroy, S. Leyvraz, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic Pancreatic Cancer: ASCO Guideline Update.

T. Conroy, P. Philip, M. Shah, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic cancer

T. Conroy, 2011 .

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Lecomte, Sophie Gourgou, T. Conroy, 2018, The New England journal of medicine.

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

T. Conroy, K. Haustermans, M. Ducreux, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

T. Conroy, M. Ychou, M. Ducreux, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series.

J. Blay, B. Coiffier, R. Bouabdallah, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early surgery for failure after chemoradiation in operable thoracic oesophageal cancer. Analysis of the non-randomised patients in FFCD 9102 phase III trial: Chemoradiation followed by surgery versus chemoradiation alone.

T. Conroy, C. Mariette, O. Bouché, 2015, European journal of cancer.

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study.

T. Conroy, G. Deplanque, J. Metges, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future directions in drug development in pancreatic cancer.

T. Conroy, M. Ducreux, A. Lambert, 2021, Seminars in oncology.

Adjuvant treatment of pancreatic cancer.

T. Conroy, M. Ducreux, 2019, Current opinion in oncology.

An update on treatment options for pancreatic adenocarcinoma

T. Conroy, M. Ducreux, I. Borbath, 2019, Therapeutic advances in medical oncology.

Sensitivity to change of the EORTC quality of life module measuring cancer‐related fatigue (EORTC QlQ‐Fa12): Results from the international psychometric validation

A. Bottomley, T. Conroy, W. Chie, 2019, Psycho-oncology.

Quality of life in long-term survivors of oropharynx carcinoma.

T. Conroy, D. Peiffert, É. Luporsi, 2002, International journal of radiation oncology, biology, physics.

An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32).

S. Schraub, N. Aaronson, A. Bottomley, 2005, European journal of cancer.

T. Conroy, C. Borg, O. Bouché, 2021, Clinical colorectal cancer.

Clinical and psychometric validation of the EORTC QLQ-CR29 questionnaire module to assess health-related quality of life in patients with colorectal cancer.

P. Fayers, M. Koller, T. Conroy, 2009, European journal of cancer.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial

T. Conroy, C. Borel, G. Deplanque, 2019, JAMA oncology.

Systemic treatment of pancreatic cancer revisited.

T. Conroy, P. Laurent-Puig, M. Ducreux, 2019, Seminars in oncology.

Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).

T. Conroy, J. Bosset, O. Bouché, 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach.

P. Fayers, A. Bottomley, T. Conroy, 2007, European journal of cancer.

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer

T. Conroy, D. Peiffert, L. Mineur, 2010, British Journal of Cancer.

Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in veterans.

P. Polak, T. Fojo, S. Bates, 2021, Seminars in oncology.

Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results

B. Chauffert, T. Conroy, C. Bascoul-Mollevi, 2020, Quality of Life Research.

Primary Thromboprophylaxis in Pancreatic Cancer Patients: Why Clinical Practice Guidelines Should Be Implemented

E. Vicaut, T. Conroy, J. Rak, 2020, Cancers.

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).

T. Conroy, O. Bouché, P. Hammel, 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.

R. Labianca, H. Friess, J. Berlin, 2018, The Lancet. Oncology.

Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4)

T. Conroy, M. Ychou, O. Bouché, 2017, Oncology.

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

M. Buyse, T. Conroy, M. Ychou, 2016, Oncotarget.

Current standards and new innovative approaches for treatment of pancreatic cancer.

T. Conroy, M. Ducreux, A. Ayav, 2016, European journal of cancer.

The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer

T. Conroy, M. Ychou, M. Ducreux, 2013, Current Oncology Reports.

Radiotherapy is unnecessary in elderly patients with localized agressive non Hodgkin's lymphoma: results of the LNH 93-4 study

T. Conroy, T. Petrella, B. Quesnel, 2002 .

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.

T. Conroy, J. Douillard, V. Boige, 2014, The Lancet. Oncology.

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

L. Collette, T. Conroy, M. Namer, 1997, European journal of cancer.

Pancreatic islet cell carcinoma with hypercalcemia: complete remission 5 years after surgical excision and chemotherapy.

T. Conroy, L. Bresler, P. Boissel, 1991, The American journal of gastroenterology.

[Clinical presentation and prognostic factors in the diagnosis of bone metastases. Apropos of a series of 578 cases].

T. Conroy, É. Luporsi, L. Malissard, 1993, Bulletin du cancer.

Metastatic pancreatic cancer: old drugs, new paradigms

T. Conroy, A. Adenis, C. Gavoille, 2011, Current opinion in oncology.

Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5‐HT3 Antagonist, in Cancer Patients Treated with Cisplatin

T. Conroy, G. Prévot, M. Spielmann, 1994, American journal of clinical oncology.

Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.

T. Conroy, P. Arveux, C. Mariette, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.

P. Fayers, M. Taphoorn, J. Reijneveld, 2018, European journal of cancer.

T. Conroy, C. Bascoul-Mollevi, J. Douillard, 2017, European journal of cancer.

Randomized multicenter phase III trial comparing two neoadjuvant chemoradiotherapy (CT-RT) regimens (RT45-Cap versus RT50-Capox) in patients (pts) with locally advanced rectal cancer (LARC): Results of the ACCORD 12/0405 PRODIGE 2.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-l-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer : Final results of a phase l i study ,

T. Conroy, M. Ducreux, D. Peiffert, 2005 .

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.

T. Conroy, J. Bosset, C. Borg, 2021, The Lancet. Oncology.

VINORELBINE IN EPIDERMOID ESOPHAGEAL CARCINOMA 167

T. Conroy, J. Seitz, A. Adenis, 2017 .

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.

M. van Glabbeke, T. Conroy, M. Glabbeke, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of Life in Patients with Oesophageal and Gastric Cancer: An Overview

T. Conroy, J. Blazeby, F. Marchal, 2007, Oncology.

Development of an EORTC module to improve quality of life assessment in patients with gastric cancer

T. Conroy, D. Alderson, C. Johnson, 2000, The British journal of surgery.

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.

A. Bottomley, M. Koller, T. Conroy, 2004, European journal of cancer.

Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial

J. Pignon, T. Conroy, M. Ychou, 2007 .

Development of an item bank for computerized adaptive testing of self-reported cognitive difficulty in cancer patients.

M. Taphoorn, J. Reijneveld, N. Aaronson, 2017, Neuro-oncology practice.

Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions

T. Conroy, C. Gavoille, A. Lambert, 2017, Therapeutic advances in gastroenterology.

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.

T. Gorlia, T. Conroy, E. Van Cutsem, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a multicenter phase II trial assessing sorafenib (S) in combination with irinotecan (i) as second- or later-line treatment in metastatic colorectal cancer (mCRC) patients (pts) with KRAS-mutated tumors (mt; NEXIRI).

T. Conroy, P. Laurent-Puig, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

French version of FACT-G: validation and comparison with other cancer-specific instruments.

S. Schraub, T. Conroy, J. Bonneterre, 2004, European journal of cancer.

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

Caen, T. Conroy, M. Barberi-Heyob, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

F. Guillemin, T. Conroy, C. Rotonda, 2011, Contemporary clinical trials.

Quality of life among disease-free survivors of rectal cancer.

F. Guillemin, T. Conroy, L. Neyton, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determinants of patient satisfaction in oncology settings from European and Asian countries: preliminary results based on the EORTC IN-PATSAT32 questionnaire.

S. Schraub, N. Aaronson, A. Bottomley, 2007, European journal of cancer.

Validation of the EORTC QLQ-SAT32 cancer inpatient satisfaction questionnaire by self- versus interview-assessment comparison.

T. Conroy, B. Asselain, C. Elie, 2004, Patient education and counseling.

Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

T. Conroy, M. Ychou, F. Penault-Llorca, 2021, ESMO Open.

T. Conroy, J. Blazeby, F. Efficace, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Development of an EORTC quality of life phase III module measuring cancer‐related fatigue (EORTC QLQ‐FA13)

A. Bottomley, T. Conroy, M. Wirtz, 2013, Psycho-oncology.

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers

S. Msika, T. Conroy, M. Copin, 2018, BMC Cancer.

Factors associated with fatigue after surgery in women with early-stage invasive breast cancer.

F. Guillemin, T. Conroy, C. Rotonda, 2013, The oncologist.

[Cancer patient's satisfaction assessment using the EORTC QLQ-SAT32: comparison between self-assessment and interview response].

T. Conroy, B. Asselain, C. Elie, 2005, Revue d'epidemiologie et de sante publique.

Efficacy and safety of nab-paclitaxel in patients with previously treated metastatic colorectal cancer: a phase II COLO-001 trial

T. Conroy, A. Lièvre, M. Ducreux, 2016, Cancer Chemotherapy and Pharmacology.

Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality of life study in breast cancer patients

F. Guillemin, T. Conroy, C. Bascoul-Mollevi, 2012, Health and Quality of Life Outcomes.

Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer.

P. Fayers, A. Bottomley, M. Koller, 2003, European journal of cancer.

Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial

C. Lavergne, T. Conroy, C. Bascoul-Mollevi, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Validation of the European Organization for Research and Treatment of Cancer QLQ‐LMC21 questionnaire for assessment of patient‐reported outcomes during treatment of colorectal liver metastases

P. Fayers, T. Conroy, O. Sezer, 2009, The British journal of surgery.

Factors affecting local control and survival after treatment of carcinoma of the rectum by endocavitary radiation: a retrospective study of 97 cases.

T. Conroy, P. Bey, L. Bresler, 2001, International journal of radiation oncology, biology, physics.

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel.

D. Aust, T. Conroy, J. Neoptolemos, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Reply to R. Glynne-Jones et al.

T. Conroy, M. Ducreux, D. Peiffert, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study.

T. Conroy, M. Ducreux, D. Peiffert, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort study

F. Guillemin, T. Conroy, F. Bonnetain, 2013, Quality of Life Research.

Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.

T. Conroy, P. Rougier, P. Arveux, 2005, Gastroenterologie clinique et biologique.

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

T. Conroy, C. Mariette, G. Piessen, 2019, European journal of cancer.

The EORTC computer-adaptive tests measuring physical functioning and fatigue exhibited high levels of measurement precision and efficiency.

N. Aaronson, M. Groenvold, M. Petersen, 2013, Journal of clinical epidemiology.

Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT‐C33) and specific complementary outpatient module (EORTC OUT‐PATSAT7)

N. Aaronson, T. Conroy, W. Chie, 2018, European journal of cancer care.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Concurrent concentrated chemoradiation therapy in squamous cell carcinoma of the esophagus: long term results of a national multicenter phase II study in 122 inoperable patients (FFCD 8803)

T. Conroy, J. Seitz, F. Dumas, 2000 .

Development and Psychometric Evaluation of an Item Bank for Computerized Adaptive Testing of the EORTC Insomnia Dimension in Cancer Patients (EORTC CAT-SL)

N. Aaronson, M. Groenvold, M. Petersen, 2019, Applied Research in Quality of Life.

ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up.

T. Conroy, O. Bouché, S. Gourgou-Bourgade, 2016 .

Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial

A. Vincent-Salomon, T. Conroy, M. Stern, 2012, Targeted Oncology.

P h ase I I T rial o f Vinorelbine i n M e tastatic Squam o us C ell E sophageal C arcinoma

T. Conroy, J. Seitz, A. Adenis, 1996 .

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

F. Guillemin, T. Conroy, C. Rotonda, 2011, Health and quality of life outcomes.

A phase III randomised trial of LV 5 FU 2 1 irinotecan versus LV 5 FU 2 alone in adjuvant high-risk colon cancer ( FNCLCC Accord 02 / FFCD 9802 )

T. Conroy, M. Ychou, M. Ducreux, 2009 .

Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients.

T. Conroy, M. Ychou, J. Douillard, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer.

F. Guillemin, T. Conroy, F. Guillemin, 1998, International journal of radiation oncology, biology, physics.

International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.

R. Labianca, L. Collette, D. Aust, 2012 .

The European organization for research and treatment of cancer — satisfaction with cancer care questionnaire: revision and extended application development

N. Aaronson, T. Conroy, W. Chie, 2017, Psycho-oncology.

Cross-cultural development of an item list for computer-adaptive testing of fatigue in oncological patients

N. Aaronson, M. Groenvold, T. Conroy, 2011, Health and quality of life outcomes.

The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer

F. Guillemin, T. Conroy, A. Omorou, 2018, Cancer.

Late cardiopulmonary toxicity after treatment for Hodgkin's disease.

T. Conroy, P. Lederlin, P. Bey, 1992, British Journal of Cancer.

Development of an EORTC module for the assessment of cancer related fatigue (EORTC FAR-15): Phase III results.

A. Bottomley, T. Conroy, B. Holzner, 2007 .

[Double paraneoplastic syndrome in a case of adenocarcinoma of the endometrium associated with Sezary syndrome].

T. Conroy, A. Barbaud, J. Schmutz, 1993, Presse medicale.

Outcome of the nonrandomized patients in the FFCD 9102 trial: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus

T. Conroy, C. Mariette, O. Bouché, 2008 .

Clinical randomized study of 5FU monitoring versus standard dose in patients with head and neck cancer: preliminary results.

T. Conroy, M. Barberi-Heyob, J. Merlin, 1994, Anticancer research.

Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer.

F. Guillemin, T. Conroy, J. Faivre, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

USE OF A DECISION ANALYSIS MODEL TO ASSESS THE COST-EFFECTIVENESS OF FDG PET IMAGING IN THE MANAGEMENT OF METACHRONOUS LIVER METASTASES OF COLORECTAL CANCER

F. Guillemin, T. Conroy, J. Faivre, 2005 .

Impact of the occurrence of a response shift on the determination of the minimal important difference in a health-related quality of life score over time

F. Guillemin, T. Conroy, F. Bonnetain, 2016, Health and Quality of Life Outcomes.

Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials

T. Conroy, S. Gourgou, C. Touraine, 2021, Quality of Life Research.

Development of an item bank for computerized adaptive test (CAT) measurement of pain

M. Hjermstad, S. Kaasa, N. Aaronson, 2015, Quality of Life Research.

Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study

T. Conroy, M. Campone, J. Raoul, 2021, Cancers.

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

[Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)].

T. Conroy, J. Seitz, F. Dumas, 2000, Gastroenterologie clinique et biologique.

[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].

T. Conroy, E. Mitry, 2011, Bulletin du cancer.

Impact of Response Shift on Time to Deterioration in Quality of Life Scores in Breast Cancer Patients

F. Guillemin, T. Conroy, F. Bonnetain, 2014, PloS one.

[Abnormal tricuspid flow in carcinoid heart disease. A case report].

T. Conroy, K. Isaaz, N. Danchin, 1990, Archives des maladies du coeur et des vaisseaux.

International validation of the EORTC CAT Core: a new adaptive instrument for measuring core quality of life domains in cancer

N. Aaronson, M. Groenvold, M. Petersen, 2020, Quality of Life Research.

Development of computerized adaptive testing (CAT) for the EORTC QLQ-C30 physical functioning dimension

P. Fayers, S. Kaasa, N. Aaronson, 2011, Quality of Life Research.

An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients (EORTC QLQ-BC23) - EORTC QLQ-BR45.

N. Aaronson, M. Sprangers, A. Bottomley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1297P Adjuvant gemcitabine is as efficient as mFOLFIRINOX in patients with GemPred+ tumor signature and resected pancreatic adenocarcinoma (PDAC): An ancillary study of the PRODIGE-24 clinical trial

T. Conroy, J. Iovanna, J. Biagi, 2022, Annals of Oncology.

Responsiveness of EORTC QLQ-C30, QLQ-CR38 and FACT-C quality of life questionnaires in patients with colorectal cancer

F. Guillemin, T. Conroy, C. Rotonda, 2011, Health and quality of life outcomes.

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial.

J. Pignon, T. Conroy, Y. Bécouarn, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

T. Conroy, S. Gourgou-Bourgade, C. Hennequin, 2009, Journal of Clinical Oncology.

Cost-minimization analysis of a phase III study of capecitabine + oxaliplatin (XELOX) vs. infusional 5-FU/LV + oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer (MCRC) in the French setting

T. Conroy, M. Ychou, M. Ducreux, 2007 .

Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.

T. Conroy, M. Ychou, C. Bascoul-Mollevi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

T. Conroy, M. Ducreux, D. Peiffert, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with 5FU plus irinotecan plus leucovorin (FOLFIRI) or capecitabine plus irinotecan XELIRI plus bevacizumab.

B. Chauffert, T. Conroy, M. Ychou, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRODIGE 2 phase III trial neoadjuvant in rectal cancer: Quality of life and results at 5 years.

T. Conroy, P. Rouanet, O. Bouché, 2016 .

Psychometric evaluation of the EORTC computerized adaptive test (CAT) fatigue item pool

M. Groenvold, M. Petersen, T. Conroy, 2013, Quality of Life Research.

477OBevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

T. Conroy, G. Deplanque, C. Borg, 2017 .